-

Bristol-Myers Squibb to Take Part at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will take part in a fireside chat at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference on Thursday, January 9, 2020 in New York. Giovanni Caforio, M.D., chairman and chief executive officer will answer questions at 10:25 a.m. ET.

Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. Materials related to the presentation will be available at the same website at the start of the live webcast. An archived edition of the session will be available later that day.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

Contacts

Media:
media@bms.com
609-252-3345

Investors:
Tim Power, 609-252-7509, timothy.power@bms.com
Nina Goworek, 908-673-9711, ngoworek@celgene.com

Bristol-Myers Squibb Company

NYSE:BMY

Release Summary
Bristol-Myers Squibb to Take Part at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference
Release Versions
$Cashtags
Hashtags

Contacts

Media:
media@bms.com
609-252-3345

Investors:
Tim Power, 609-252-7509, timothy.power@bms.com
Nina Goworek, 908-673-9711, ngoworek@celgene.com

More News From Bristol-Myers Squibb Company

Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA...

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

PRINCETON, N.J.--(BUSINESS WIRE)--U.S. FDA Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma...

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026...
Back to Newsroom